Mingzu Huang

  • Citations Per Year
Learn More
In order to confirm the efficacy, tolerability, and baseline prognostic factors of an epirubicin (EPR)-containing triplet regimen, the EOF5 regimen, in patients with metastatic gastric cancer (MGC), we conducted the phase II trial and retrospective analysis. MGC patients received the EOF5 regimen (EPR 50 mg/m2 and oxaliplatin (OX) 130 mg/m2 on day 1(More)
Previous case-control studies on the association of the angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism with gastric cancer were controversial. A meta-analysis was conducted to further evaluate the association between polymorphism in the ACE gene I/D and gastric cancer. We searched MEDLINE (PubMed), EMBASE, Web of Science, and(More)
  • 1